Home > Boards > US Listed > Biotechs >

Halozyme Therapeutics (HALO)

Add HALO Price Alert      Hide Sticky   Hide Intro
Moderator: Fred Kadiddlehopper
Search This Board: 
Last Post: 3/3/2021 5:40:08 PM - Followers: 91 - Board type: Free - Posts Today: 0


Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases.

The company's Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, the company has received FDA approval for two products: Cumulase® and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter Healthcare Corporation. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Halozyme is a therapeutically driven biopharmaceutical company developing and commercializing recombinant human enzymes to provide enhanced and innovative alternatives that improve the practice of medicine. Halozyme is focused on providing life-saving and life-enhancing solutions to the drug delivery, oncology, and dermatology markets.


Halozyme is a therapeutically driven biopharmaceutical company developing and commercializing recombinant human enzymes to provide enhanced and innovative alternatives that improve the practice of medicine. Halozyme is focused on providing life-saving and life-enhancing solutions to the drug delivery, oncology, and dermatology markets.

The foundation of our capabilities is our recombinant human hyaluronidase enzyme, rHuPH20, which temporarily degrades hyaluronan, a structural protein in the interstitial space. This temporary alteration provides an opportunistic window that allows the delivery of injectable biologics such as monoclonal antibodies, as well as small molecules and fluids. With our enzyme, many pharmaceuticals that would normally be injected intravenously (IV) can be administered subcutaneously (SC). This change in route of delivery may improve patient convenience, enhance pharmacokinetics, boost efficacy, extend the product lifecycle, and reduce cost, in addition to other attributes.

Four key internal programs comprise our current proprietary product development portfolio. The endocrinology franchise consists of Insulin-PH20, which applies our PH20 enzyme to currently approved and marketed insulin products. The oncology franchise consists of PEGPH20, a new molecular entity administered intravenously that targets the external environment of tumor cells, and Chemophase, which utilizes the PH20 enzyme for local administration in bladder cancer. Our lead enzyme in the dermatology franchise, HTI-501, is a new molecular entity which digests collagen and may have applications in both medical and aesthetic dermatology such as cellulite.

Our product development pipeline also includes three distinct partnered programs with two companies; Roche and Baxter BioScience for Enhanze technology, and a partnership with Baxter Medication Delivery for Hylenex, our FDA-approved drug. These partnered programs validate our technology and may generate clinical and commercial milestone revenue based on the achievement of pre-specified events along with sales royalties when products reach the commercial stage. We utilize the cash milestone payments generated from the partnered programs as a source of development funding for our proprietary pipeline projects.


Our endocrinology development activity focuses on insulin, a mainstay of treatment for people with diabetes. This program combines our PH20 hyaluronidase enzyme with insulin, a frequently prescribed, commercially successful pharmaceutical already approved and on the market.

Insulin – Developing a best-in-class profile

We believe that the combination of our PH20 enzyme with existing, meal time insulin products such as regular insulin or a fast acting analog could lead to a best-in-class product that more closely mimics the release of natural insulin in the body. The results of a Phase 1 study, where we combined PH20 with Humulin® R (regular human insulin) and with Humalog® (insulin lispro), demonstrated significantly faster and higher insulin plasma concentrations compared to either insulin alone. Faster acting insulin could provide patient benefits such as reduced hypoglycemia, lower intra-subject variability, and less weight gain. These potential benefits would be significant but must first be demonstrated and proven in clinical development.

Our first Phase 2 clinical trial with insulin began in October 2008 and enrolled Type 1 diabetic patients. Data presented from our Phase 1 trial showed that the administration of regular insulin and an insulin analog with our PH20 enzyme led to faster insulin absorption and more rapid effects than either insulin alone. Our Phase 2 trial is designed to demonstrate similar results in Type 1 diabetic patients. We hope to present preliminary Phase 2 results at the American Diabetes Association meeting in June. Additional clinical trials are planned in 2009.


Hyaluronan (HA) is a component of the extracellular matrix that frequently accumulates in human cancers. The quantity of HA produced by the tumor cells directly correlates with increased tumor growth and metastasis and it has been linked with tumor progression and poor prognosis. Previous clinical trials of bovine hyaluronidase showed promise in enhancing chemotherapy regimens using adjunctive systemic hyaluronidase in chemo-refractory patients. In animal studies the removal of HA from tumors with hyaluronidase has demonstrated improved survival, suppression of tumor growth, and enhanced efficacy of certain anti-cancer drugs. Chemotherapeutic agents may be able to better penetrate the tumor once the HA has been removed.

We have also observed significant reduction of tumor interstitial fluid pressure (IFP) following the administration of rHuPH20 in solid tumors grown in mice. Tumor interstitial pressure is widely believed to be an important factor limiting the access of cytostatic regimens to solid tumors. By digesting the HA gel, rHuPH20 may reduce IFP in the tumor and promote more effective delivery of chemotherapy throughout the tumor. This could potentially lead to better patient outcomes and increased survival.

Our PEGPH20 program utilizes pegylated hyaluronidase that allows for intravenous administration to degrade the HA that surrounds tumor cells. The Chemophase program applies the hyaluronidase enzyme along with mitomycin C directly into the bladder where the enzyme can hydrolyze the HA produced by the cancerous bladder cells. Unlike tumor cells, normal cells do not produce HA in this manner and appear not to be adversely affected by the enzyme.

PEGPH20 for Solid Tumors

We are investigating pegylated-rHuPH20, or PEGPH20, a new molecular entity, as a candidate for the systemic treatment of tumors rich in hyaluronan, or HA. Pegylation refers to the attachment of polyethylene glycol to our rHuPH20 enzyme, which extends its half life from less than 30 seconds to more than 24 hours. Numerous solid tumors, including prostate, breast, pancreas, colon and non-small cell lung, accumulate HA that forms a halo like coating over the surface of the tumor cell.

In preclinical studies, PEGPH20 has been shown to remove the HA coating surrounding several tumor cell lines. Treatment of PC3 (a prostate cancer cell line that produces HA) tumor bearing mice with PEGPH20 as a single agent demonstrated approximately 70% tumor growth inhibition relative to controls. Repeat dosing with PEGPH20 produced a sustained depletion of HA in the tumor microenvironment. For tumor models that do not produce HA, the presence of PEGPH20 has no effect. An estimated 20% to 40% of certain solid tumors may produce HA.

Administration of the combination of PEGPH20 with docetaxel or with liposomal doxorubicin in HA producing animal tumor models produced a significant survival advantage for the combination relative to either chemotherapeutic agent alone. Therefore, based on these animal studies and other tests conducted by Halozyme, PEGPH20 may represent a potentially innovative treatment approach against tumors that produce HA.

PEGPH20 recently started its first Phase 1 clinical trial which will evaluate the agent over a range of doses. The study will enroll up to 46 advanced cancer patients who will receive treatment cycles of intravenous PEGPH20 as a single agent twice weekly for three weeks followed by one week without dosing. Patients may continue subsequent cycles at their assigned dose as long as there is no tumor progression and no unacceptable toxicity. Groups of four to eight patients will be in each dosage cohort. The primary outcome measures of the study will be to evaluate safety and tolerability of PEGPH20 and to determine the recommended single agent Phase 2 dose. Secondary objectives will be to determine pharmacokinetics, obtain dose limiting toxicities, and observe patients for any evidence of anti-tumor activity.


Chemophase is a chemoadjuvant we have investigated for possible use in the treatment of patients with superficial bladder cancer, which represents a smaller potential market than our other proprietary pipeline opportunities. The Chemophase program combines our PH20 enzyme with mitomycin C, a cytotoxic drug, for direct administration into the bladder immediately after transurethral resection of bladder tumors (TURBT), a standard surgical treatment for the disease. Many bladder tumor cells produce high quantities of HA and thus treatment to remove the HA coating could increase their exposure to mitomycin C. This may lead to a lower recurrence of the cancer and a better prognosis for patients.

In June 2008, we announced the interim results of a Phase I/IIa clinical trial in which the Chemophase combination treatment of mitomycin C plus rHuPH20 enzyme was well tolerated and appears safe. The study reported no dose-limiting toxicities and no observed side effects attributable to the enzyme. An ongoing safety trial involves the immediate post operative (IPOP) administration of PH20 and mitomycin directly into the bladder of patients after a TURBT procedure. 


The foundation of our dermatology program is HTI-501, a human lysosomal proteinase that degrades collagen. It may be useful in the treatment of both medical and aesthetic dermatologic conditions such as cellulite, Dupuytren’s contracture and Peyronie’s disease. This pH sensitive enzyme demonstrates activity under mildly acidic conditions but shows no activity at normal physiologic pH. This attribute may be harnessed to exert control over the duration and location of the enzyme’s therapeutic activity.

Tests with HTI-501 in several animal models have produced encouraging results and our pre-clinical investigations of the enzyme will continue throughout 2009.


Enhanze™ Technology, a proprietary drug delivery platform using Halozyme’s first approved enzyme, rHuPH20, is our broader technology opportunity that can potentially lead to partnerships with other pharmaceutical companies. When co-formulated with other injectable drugs, Enhanze Technology may facilitate the penetration and dispersion of these drugs by temporarily opening flow channels under the skin.  

Molecules as large as 200 nanometers may pass freely through the extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform which does not permanently alter the architecture of the skin. The principal focus of our Enhanze Technology platform is the use of rHuPH20 to facilitate subcutaneous or intramuscular routes of administration for large molecule biological therapeutics. We are seeking partnerships with pharmaceutical companies that market drugs requiring or benefiting from injection via the subcutaneous or intramuscular routes that could benefit from this technology. In December 2006, we signed our first Enhanze Technology partnership with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche, Inc. In September 2007, we signed our second Enhanze Technology partnership with Baxter Healthcare Corporation and Baxter Healthcare S.A.


Full prescribing information is available below or at  www.hylenex.com

Hylenex is a human recombinant formulation of rHuPH20 to facilitate the absorption and dispersion of other injected drugs or fluids. When injected under the skin or in the muscle, hyaluronidase can digest the hyaluronic acid gel, allowing for temporarily enhanced penetration and dispersion of other injected drugs or fluids. We filed a New Drug Application (NDA) in March 2005 and we received approval of our Hylenex NDA in December 2005.

Enzymatically- Augmented Subcutaneous Infusion (EASI):

Hylenex may facilitate subcutaneous delivery of fluids up to one liter without the need for intravenous access, a procedure known as EASI. Importantly, EASI for fluid replacement in terminal patients may be achieved with limited or no need for nursing assistance. Over 1.1 million subcutaneous fluid infusions are performed per year with hospice patients alone (Source: Company estimates based on National Hospice and Palliative Care Organization data, 2001). In addition, over 500 million infusion bags are utilized annually in the United States, some of which could potentially convert to EASI using Hylenex, giving rise to additional market potential (Source: B. Braun, 2003).


During January 2006, we completed the INcreased Flow Utilizing Subcutaneously-Enabled Lactated Ringer’s clinical trial, or INFUSE-LR study, which was designed to determine the subcutaneous (Sub-Q) infusion flow rate of Lactated Ringer’s solution with and without Hylenex, determine the Sub-Q infusion flow rate dose response to Hylenex over one order of magnitude of dose, and assess safety and tolerability. This prospective, double-blind, randomized, placebo-controlled, within-subject, dose-comparison study enrolled 54 volunteer subjects who received Sub-Q infusions simultaneously in both upper arms through 24 gauge catheters.

INFUSE-Morphine Study:

During October 2006, we completed the INcreased Flow Utilizing Subcutaneously-Enabled Morphine clinical trial, or INFUSE-Morphine study, which was designed to determine the time to maximal blood levels of morphine after subcutaneous administration with and without Hylenex, to determine the time to maximal blood levels after intravenous administration of morphine, and to assess safety and tolerability. This prospective, double-blind, randomized, placebo-controlled, within-subject, dose-comparison study enrolled 12 evaluable patients who received Sub-Q infusions.

For full prescribing information, visit  www.hylenex.com or www.baxter.com.


Cumulase is an ex vivo (used outside of the body) formulation of rHuPH20 to replace the bovine enzyme currently used for the preparation of oocytes (eggs) prior to IVF during the process of intracytoplasmic sperm injection (ICSI), in which the enzyme is an essential component. The enzyme strips away the hyaluronic acid that surrounds the oocyte. This allows the clinician to then perform the ICSI procedure, injecting the sperm into the oocyte. The FDA considers hyaluronidase IVF products to be medical devices subject to 510(k) approval and we filed our 510(k) application during September 2004.

We received FDA clearance in April 2005. We launched Cumulase in the European Union and in the United States in June 2005. We believe the total ICSI market consisted of an estimated 500,000 intracytoplasmic sperm injection cycles worldwide in 2005 (Source: CDC, 2001; ESHRE, 2002).

Visit www.cumulase.com for more information.

Informative Links 

(Institutional Holdings)

(Big Block Holders from CNBC)

(SEC filings search from SEC.gov Edgar)

http://www.nasdaqtrader.com/Trader.aspx?id=shortinterest (Short Interest)

(Analyst Ratings)

(Insider Transactions)

(Clinical Trials)

Clinicals & Partners

Halozyme and Roche enter agreement for the application of Enhanze, a novel technology to improve drug delivery

(Halozyme and Roche presents “Developing and Managing Strategic Alliances” at the SCRIP conference
May 15-16, 2007  Berlin, Germany)

Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously (Enhanze 3-16-08) 

Halozyme and Baxter Expand Global HYLENEX Collaboration

http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=IROL-secToc&TOC=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvY29udGVudHMueG1sP2lwYWdlPTU0NDgxMjkmcmVwbz10ZW5r (Feb. 12, 2008 Slide Show Presentation)

Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 
Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences

Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference

Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal Remodeling With HTI-501, a Lysosomal Proteinase

Phase I/II data showed that Enhanze Technology™ enabled subcutaneous administration of a monthly dose of GAMMAGARD LIQUID in patients with Primary Immunodeficiency

http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1163612&highlight=Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability

Cheetah full ADA presentation

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial

Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients

Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target

Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Halozyme Deprioritizes Bisphosphonate Program to Reallocate Resources to More Commercially Attractive Internal Programs

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial With Second Biologic

Halozyme Therapeutics Presents Positive Pre-Clinical Single Agent Data for PEGPH20

AACR presentations show that PEGPH20 produces anti-cancer activity in models of breast, prostate, and brain metastases that produce hyaluronan

Phase 1 Study for Halozyme's Insulin-PH20 Published, Highlights Findings for Faster Acting Insulin Formulations
-- Insulin-PH20 Combinations Demonstrated Significantly Faster Glucose Metabolism --


 Accelerated Insulin Pharmacokinetics and Improved Glycemic Control in T1DM Patients by
Coadministration of Prandial Insulin with Recombinant Human Hyaluronidase


Halozyme Announces Roche Selects Fifth Exclusive Biologic Target

Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID(TM) with rHuPH20 Enzyme 


 First patient dosed in trial with third Roche biologic formulated with Halozyme’s recombinant human hyaluronidase enzyme

Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration
Data from the First Pediatric Rehydration Study, INFUSE-PEDS 1, Published Today in Pediatrics


Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)



Earnings Transcripts

Halozyme Therapeutics Q4 2007 Earnings Call Transcript

Halozyme Therapeutics Inc. Q1 2008 Earnings Call Transcript

Halozyme Therapeutics Inc. Q2 2008 Earnings Call Transcript

Halozyme Therapeutics, Inc. Q3 2008 Earnings Call Transcript

Halozyme Therapeutics, Inc. Q4 2008 Earnings Call Transcript

Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript

Links to understanding Clinical results

Shares Outstanding: 91,095,288
Float: 73.21M

(O-T How the market is manipulated and companies destroyed)

Halozyme Therapeutics Inc.
11588 Sorrento Valley Road
Suite 17
San Diego, CA 92121
United States
Phone: 858-794-8889

Halozyme Contact
Robert H. Uhl
Senior Director Investor Relations

(Disclaimer) Do your own DD and confirm anything said on this board.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
HALO News: Current Report Filing (8-k) 03/01/2021 04:08:08 PM
HALO News: Current Report Filing (8-k) 02/25/2021 06:08:01 AM
HALO News: Halozyme Therapeutics prices $700M of private debt offering 02/25/2021 05:02:56 AM
HALO News: Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 02/24/2021 10:41:00 PM
HALO News: Current Report Filing (8-k) 02/23/2021 04:17:53 PM
#5421  Sticky Note Halo Royalty chart Fred Kadiddlehopper 01/10/18 11:09:12 AM
#6389   The entire Biotech Industry is getting hammered. Most Howeeme 03/03/21 05:40:08 PM
#6388   The first round of stock buybacks and the biotechinvestor1 03/03/21 01:41:52 PM
#6387   It was a clear story before, easily understood, Fred Kadiddlehopper 03/03/21 01:30:33 PM
#6386   I look at it as discount shopping. I biotechinvestor1 03/03/21 12:30:00 PM
#6385   This deal was is not being received well. Fred Kadiddlehopper 03/03/21 12:01:32 PM
#6384   I think they will make an acquisition. Wouldn’t Howeeme 03/02/21 10:57:45 PM
#6383   The announcements of $500 million in stock buybacks biotechinvestor1 03/02/21 05:03:02 PM
#6382   That’s an important and consequential advantage for enhanze/halo. biotechinvestor1 03/02/21 01:09:17 AM
#6381   Good find. Thanks and I hope you are maumar 03/01/21 05:13:53 PM
#6380   Read the recently published meta analysis of Enhanze biotechinvestor1 02/27/21 02:36:26 PM
#6379   Sometimes the market gives you a gift. Buy biotechinvestor1 02/27/21 11:24:45 AM
#6378   Halo will raise 805 million with this offering. Howeeme 02/26/21 10:35:30 PM
#6377   I’m adding cash on the balance sheet to Howeeme 02/26/21 10:33:01 PM
#6376   PS. I know there is dilution at the biotechinvestor1 02/26/21 08:46:11 PM
#6375   Read the press release and put yourself in biotechinvestor1 02/26/21 08:36:36 PM
#6374   They are repurchasing the old notes so they maumar 02/26/21 08:28:15 PM
#6373   All of these short term moves are besides biotechinvestor1 02/26/21 02:45:49 PM
#6372   The 20% hair cut will entice CFO to biotechinvestor1 02/26/21 10:20:17 AM
#6371   20% down from the recent high and now biotechinvestor1 02/26/21 10:05:18 AM
#6370   Doubtful on that one. More like Xoma or Howeeme 02/26/21 08:46:17 AM
#6369   Maybe she's looking at Avid. Good match Roger1 02/26/21 08:39:09 AM
#6368   I interpret it as she’s not talking. Just Howeeme 02/26/21 08:28:44 AM
#6367   In asnwering a question about possible acquisitions, Helen Fred Kadiddlehopper 02/26/21 07:14:58 AM
#6366   Figure we picked up somewhere in vicinity of Howeeme 02/25/21 11:10:53 PM
#6365   I just read the PR on the issuance halofan 02/25/21 02:19:47 PM
#6364   Is it possible that some institutional investors (since halofan 02/25/21 01:28:01 PM
#6363   I have never been a huge fan of Fred Kadiddlehopper 02/25/21 12:46:53 PM
#6362   I agree and think it is a generally Fred Kadiddlehopper 02/25/21 12:42:47 PM
#6361   The PR says they expect to issue 9.08M maumar 02/25/21 12:30:09 PM
#6360   New All-time Intra-day high yesterday: $56.40 Fred Kadiddlehopper 02/25/21 10:39:21 AM
#6359   The one thing that confuses me about the Fred Kadiddlehopper 02/25/21 10:15:28 AM
#6358   A gift, i.e. a chance to buy more biotechinvestor1 02/25/21 10:11:48 AM
#6357   This deal is being used to retire a Fred Kadiddlehopper 02/25/21 10:10:01 AM
#6356   I don't really understand this but why do maumar 02/25/21 10:06:51 AM
#6355   If you read the press release from 11/13/19 biotechinvestor1 02/25/21 09:54:44 AM
#6354   Agreed that HALO was not the source. The Fred Kadiddlehopper 02/25/21 07:05:13 AM
#6353   In fifteen years the company seems to have Howeeme 02/25/21 07:03:04 AM
#6352   Yes, this is very good new and we Fred Kadiddlehopper 02/25/21 06:52:39 AM
#6351   Do you think word was out yesterday? Fred Kadiddlehopper 02/25/21 06:47:50 AM
#6350   Last time they issued a convertible note was biotechinvestor1 02/25/21 12:30:01 AM
#6349   One more thing. Interest rate .25 percent. Virtually Howeeme 02/24/21 11:32:11 PM
#6348   Company just announced they raised an extra 200 Howeeme 02/24/21 11:17:17 PM
#6347   Interesting trade pattern and volume today. I expect biotechinvestor1 02/24/21 02:17:14 PM
#6346   Good call Fred. Analyst will have to catch biotechinvestor1 02/24/21 12:20:03 PM
#6345   I didn't hear anything that would cause me Fred Kadiddlehopper 02/24/21 12:11:34 PM
#6344   I haven't seen any upgrades cross the wires yet. Fred Kadiddlehopper 02/24/21 11:53:53 AM
#6343   I think this is the trial that may maumar 02/24/21 11:45:27 AM
#6342   Maybe it has to do with this: NIH is biotechinvestor1 02/24/21 11:28:11 AM
#6341   It feels like the market is anticipating something biotechinvestor1 02/24/21 10:09:59 AM
#6340   Yes, I noticed that too. Hopefully, it'll become maumar 02/24/21 09:51:28 AM
Consent Preferences